NCT00252304

Brief Summary

The aim of this study is to assess whether zinc given as adjuvant therapy to standard antibiotic treatment in children hospitalized for severe pneumonia reduces the duration of the severe illness and risk of treatment failure. A randomized double blind placebo controlled clinical trial will be conducted at the Kanti Hospital.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
641

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Jan 2006

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 10, 2005

Completed
1 day until next milestone

First Posted

Study publicly available on registry

November 11, 2005

Completed
2 months until next milestone

Study Start

First participant enrolled

January 1, 2006

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2008

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2008

Completed
Last Updated

October 6, 2009

Status Verified

October 1, 2009

Enrollment Period

2.5 years

First QC Date

November 10, 2005

Last Update Submit

October 2, 2009

Conditions

Keywords

Child, severe pneumonia, Zinc, Nepal, therapeutic

Outcome Measures

Primary Outcomes (2)

  • Time to cessation of severe pneumonia

    Within 2 weeks after enrollment

  • The period starting from enrolment to the beginning of a 24-hour consecutive period of absence of lower chest indrawing, of hypoxia and of any danger signs.

    Recovery from pneumonia within 2 weeks

Study Arms (2)

Zinc

EXPERIMENTAL

Zinc sulphate 10 or 20 mg per day

Drug: Zinc (zinc sulphate)

Placebo

PLACEBO COMPARATOR

Placebo

Drug: Placebo

Interventions

Dissolvable zinc tablet 10 mg elemental zinc per day for infants 20 mg elemental zinc per day for children 12 to 35 months

Also known as: Produced by Nutriset, Malaunay, France
Zinc

Placebo

Also known as: Produced by Nutriset, Malaunay, France
Placebo

Eligibility Criteria

Age2 Months - 35 Months
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Children aged 2- 35 months with a history of cough (duration \<14days) and difficult breathing of \</= 72hours' duration, with lower chest indrawing.
  • Availability of informed consent.

You may not qualify if:

  • Children with severe wasting (\<70% NCHS median weight for height)
  • Severe anemia (hemoglobin \<7 gm/dl.)
  • Presence of heart disease with or without signs of cardiac failure.
  • Child with a chronic cough (lasting for ≥14 days)
  • Documented tuberculosis with ongoing treatment.
  • Associated other severe diseases that require special care or surgical intervention.
  • Children with concomitant diarrhea with some/severe dehydration
  • Children with a history of recurrent wheezing
  • Children enrolled in the study within the last 6 months of this visit

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Kanti Children Hospital

Kathmandu, Nepal

Location

Related Publications (15)

  • Nepal Demographic and Health Survey, 2001

    BACKGROUND
  • Nepal Ministry of Health, Department of Health Services Annual Report 2000- 2001, Kathmandu

    BACKGROUND
  • Shankar AH, Prasad AS. Zinc and immune function: the biological basis of altered resistance to infection. Am J Clin Nutr. 1998 Aug;68(2 Suppl):447S-463S. doi: 10.1093/ajcn/68.2.447S.

    PMID: 9701160BACKGROUND
  • Bahl R, Bhandari N, Hambidge KM, Bhan MK. Plasma zinc as a predictor of diarrheal and respiratory morbidity in children in an urban slum setting. Am J Clin Nutr. 1998 Aug;68(2 Suppl):414S-417S. doi: 10.1093/ajcn/68.2.414S.

    PMID: 9701154BACKGROUND
  • Bhutta ZA, Black RE, Brown KH, Gardner JM, Gore S, Hidayat A, Khatun F, Martorell R, Ninh NX, Penny ME, Rosado JL, Roy SK, Ruel M, Sazawal S, Shankar A. Prevention of diarrhea and pneumonia by zinc supplementation in children in developing countries: pooled analysis of randomized controlled trials. Zinc Investigators' Collaborative Group. J Pediatr. 1999 Dec;135(6):689-97. doi: 10.1016/s0022-3476(99)70086-7.

    PMID: 10586170BACKGROUND
  • Bhandari N, Bahl R, Taneja S, Strand T, Molbak K, Ulvik RJ, Sommerfelt H, Bhan MK. Substantial reduction in severe diarrheal morbidity by daily zinc supplementation in young north Indian children. Pediatrics. 2002 Jun;109(6):e86. doi: 10.1542/peds.109.6.e86.

    PMID: 12042580BACKGROUND
  • Brown KH. Effect of infections on plasma zinc concentration and implications for zinc status assessment in low-income countries. Am J Clin Nutr. 1998 Aug;68(2 Suppl):425S-429S. doi: 10.1093/ajcn/68.2.425S.

    PMID: 9701156BACKGROUND
  • Beisel WR. Zinc metabolism in infection. In: Brewer GJ, Prasad AS, eds. Zinc metabolism: current aspects in health and disease. New York: Alan R Liss, 1977: 973-977

    BACKGROUND
  • Cousins RJ, Leinart AS. Tissue-specific regulation of zinc metabolism and metallothionein genes by interleukin 1. FASEB J. 1988 Oct;2(13):2884-90. doi: 10.1096/fasebj.2.13.2458983.

    PMID: 2458983BACKGROUND
  • Strand TA, Hollingshead SK, Julshamn K, Briles DE, Blomberg B, Sommerfelt H. Effects of zinc deficiency and pneumococcal surface protein a immunization on zinc status and the risk of severe infection in mice. Infect Immun. 2003 Apr;71(4):2009-13. doi: 10.1128/IAI.71.4.2009-2013.2003.

    PMID: 12654820BACKGROUND
  • Bhutta ZA, Bird SM, Black RE, Brown KH, Gardner JM, Hidayat A, Khatun F, Martorell R, Ninh NX, Penny ME, Rosado JL, Roy SK, Ruel M, Sazawal S, Shankar A. Therapeutic effects of oral zinc in acute and persistent diarrhea in children in developing countries: pooled analysis of randomized controlled trials. Am J Clin Nutr. 2000 Dec;72(6):1516-22. doi: 10.1093/ajcn/72.6.1516.

    PMID: 11101480BACKGROUND
  • Strand TA, Chandyo RK, Bahl R, Sharma PR, Adhikari RK, Bhandari N, Ulvik RJ, Molbak K, Bhan MK, Sommerfelt H. Effectiveness and efficacy of zinc for the treatment of acute diarrhea in young children. Pediatrics. 2002 May;109(5):898-903. doi: 10.1542/peds.109.5.898.

    PMID: 11986453BACKGROUND
  • Brooks WA, Yunus M, Santosham M, Wahed MA, Nahar K, Yeasmin S, Black RE. Zinc for severe pneumonia in very young children: double-blind placebo-controlled trial. Lancet. 2004 May 22;363(9422):1683-8. doi: 10.1016/S0140-6736(04)16252-1.

    PMID: 15158629BACKGROUND
  • Haugen J, Basnet S, Hardang IM, Sharma A, Mathisen M, Shrestha P, Valentiner-Branth P, Strand TA. Vitamin D status is associated with treatment failure and duration of illness in Nepalese children with severe pneumonia. Pediatr Res. 2017 Dec;82(6):986-993. doi: 10.1038/pr.2017.71. Epub 2017 Aug 16.

  • Basnet S, Shrestha PS, Sharma A, Mathisen M, Prasai R, Bhandari N, Adhikari RK, Sommerfelt H, Valentiner-Branth P, Strand TA; Zinc Severe Pneumonia Study Group. A randomized controlled trial of zinc as adjuvant therapy for severe pneumonia in young children. Pediatrics. 2012 Apr;129(4):701-8. doi: 10.1542/peds.2010-3091. Epub 2012 Mar 5.

MeSH Terms

Conditions

Pneumonia

Interventions

ZincZinc Sulfate

Condition Hierarchy (Ancestors)

Respiratory Tract InfectionsInfectionsLung DiseasesRespiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Metals, HeavyElementsInorganic ChemicalsTransition ElementsMetalsSulfatesSulfuric AcidsSulfur AcidsSulfur CompoundsZinc Compounds

Study Officials

  • Sudha Basnet, MD

    Department of Child Health, Institute of Medicine, Tribhuwan University, Katmandu, Nepal

    PRINCIPAL INVESTIGATOR
  • Tor A Strand, MD, PhD

    Centre For International Health

    STUDY DIRECTOR
  • Halvor Sommerfelt, MD, PhD

    Centre For International Health

    STUDY CHAIR
  • Nita Bhandari, MBBS, PhD

    Centre For International Health

    STUDY CHAIR
  • Prakash S Shrestha, MD

    Child Health Research Project, Department of Child Health, Institute of Medicine, Maharajganj:

    STUDY DIRECTOR
  • Ramesh K Adhikari, MD

    Child Health Research Project, Department of Child Health, Institute of Medicine, Maharajganj:

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

November 10, 2005

First Posted

November 11, 2005

Study Start

January 1, 2006

Primary Completion

July 1, 2008

Study Completion

July 1, 2008

Last Updated

October 6, 2009

Record last verified: 2009-10

Locations